Table 3.
Indications for hematopoietic cell transplantation in adults (generally age ≥18 years)
| Indication and Disease Status | Allogeneic HCT | Autologous HCT |
|---|---|---|
| Acute myeloid leukemia | ||
| CR1, low risk | N | C |
| CR1, intermediate risk | S | C |
| CR1, high risk | S | C |
| CR2 | S | C |
| CR3+ | C | C |
| Not in remission | C | N |
| Acute promyelocyte leukemia | ||
| CR1 | N | N |
| CR2, molecular remission | C | S |
| CR2, not in molecular remission | S | N |
| CR3+ | C | N |
| Not in remission | C | N |
| Relapse after autologous transplant | C | N |
| Acute lymphoblastic leukemia | ||
| CR1, standard risk | S | C |
| CR1, high risk | S | N |
| CR2 | S | C |
| CR3+ | C | N |
| Not in remission | C | N |
| Chronic myeloid leukemia | ||
| Chronic phase 1, TKI intolerant | C | N |
| Chronic phase 1, TKI refractory | C | N |
| Chronic phase 2+ | S | N |
| Accelerated phase | S | N |
| Blast phase | S | N |
| Myelodysplastic syndromes | ||
| Low/intermeditate-1 risk | C | N |
| Intermediate-2/high risk | S | N |
| Therapy related AML/MDS | ||
| CR1 | S | N |
| Myelofibrosis & myeloproliferative diseases | ||
| Primary, low risk | C | N |
| Primary, intermediate/high risk | C | N |
| Secondary | C | N |
| Hypereosinophilic syndromes, refractory | R | N |
| Plasma cell disorders | ||
| Myeloma, initial response | D | S |
| Myeloma, sensitive relapse | C | S |
| Myeloma, refractory | C | C |
| Plasma cell leukemia | C | C |
| Primary amyloidosis | N | C |
| POEMS syndrome | N | R |
| Relapse after autologous transplant | C | C |
| Hodgkin lymphoma | ||
| CR1 (PET negative) | N | N |
| CR1 (PET positive) | N | C |
| Primary refractory, sensitive | C | S |
| Primary refractory, resistant | C | N |
| First relapse, sensitive | S | S |
| First relapse, resistant | C | N |
| Second or greater relapse | C | S |
| Relapse after autologous transplant | C | N |
| Diffuse large B-cell lymphoma | ||
| CR1 (PET negative) | N | N |
| CR1 (PET positive) | N | C |
| Primary refractory, sensitive | C | S |
| Primary refractory, resistant | C | N |
| First relapse, sensitive | C | S |
| First relapse, resistant | C | N |
| Second or greater relapse | C | S |
| Relapse after autologous transplant | C | N |
| Follicular lymphoma | ||
| CR1 | N | C |
| Primary refractory, sensitive | S | S |
| Primary refractory, resistant | S | N |
| First relapse, sensitive | S | S |
| First relapse, resistant | S | N |
| Second or greater relapse | S | S |
| Transformation to high grade lymphoma | C | S |
| Relapse after autologous transplant | C | N |
| Mantle cell lymphoma | ||
| CR1/PR1 | C | S |
| Primary refractory, sensitive | S | S |
| Primary refractory, resistant | C | N |
| First relapse, sensitive | S | S |
| First relapse, resistant | C | N |
| Second or greater relapse | C | S |
| Relapse after autologous transplant | C | N |
| T-cell lymphoma | ||
| CR1 | C | C |
| Primary refractory, sensitive | C | S |
| Primary refractory, resistant | C | N |
| First relapse, sensitive | C | S |
| First relapse, resistant | C | N |
| Second or greater relapse | C | C |
| Relapse after autologous transplant | C | N |
| Lymphoplasmacytic lymphoma | ||
| CR1 | N | N |
| Primary refractory, sensitive | N | C |
| Primary refractory, resistant | R | N |
| First or greater relapse, sensitive | R | C |
| First or greater relapse, resistant | R | N |
| Relapse after autologous transplant | C | N |
| Burkitt's lymphoma | ||
| First remission | C | C |
| First or greater relapse, sensitive | C | C |
| First or greater relapse, resistant | C | N |
| Relapse after autologous transplant | C | N |
| Cutaneous T-cell lymphoma | ||
| Relapse | C | C |
| Relapse after autologous transplant | C | N |
| Plasmablastic lymphoma | ||
| CR1 | R | R |
| Relapse | R | R |
| Chronic lymphocytic leukemia | ||
| High risk, first or greater remission | C | N |
| T-cell prolymphocytic leukemia | R | R |
| B-cell, prolymphocytic leukemia | R | R |
| Transformation to high grade lymphoma | C | C |
| Solid tumors | ||
| Germ cell tumor, relapse | N | C |
| Germ cell tumor, refractory | N | C |
| Ewing's sarcoma, high risk | N | C |
| Breast cancer, adjuvant high risk | N | D |
| Breast cancer, metastatic | D | D |
| Renal cancer, metastatic | D | N |
| Non-malignant diseases | ||
| Severe aplastic anemia, new diagnosis | S | N |
| Severe aplastic anemia, relapse/refractory | S | N |
| Fanconi's anemia | R | N |
| Dyskeratosis congenita | R | N |
| Sickle cell disease | C | N |
| Thalassemia | D | N |
| Hemophagocytic syndromes, refractory | R | N |
| Mast cell diseases | R | N |
| Common variable immunodeficiency | R | N |
| Wiskott-Aldrich syndrome | R | N |
| Chronic granulomatous disease | R | N |
| Multiple sclerosis | N | D |
| Systemic sclerosis | N | D |
| Rheumatoid arthritis | N | D |
| Systemic lupus erythematosus | N | D |
| Crohn's disease | N | D |
| Polymyositis-dermatomyositis | N | D |
Recommendation categories (see text for definition): Standard of care (S); Standard of care, clinical evidence available (C); Standard of care, rare indication (R); Developmental (D); Not generally recommended (N)
Rather than provide a long and evolving list of unique rare diseases, the indications table shows a concise categorical list together with selected unique diagnoses for which transplant is most frequently offered